vs
EPLUS INC（PLUS）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED THERAPEUTICS Corpの直近四半期売上が大きい（$790.2M vs $614.8M、EPLUS INCの約1.3倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 5.7%、差は40.4%）。EPLUS INCの前年同期比売上増加率が高い（20.3% vs 7.4%）。過去8四半期でUNITED THERAPEUTICS Corpの売上複合成長率が高い（8.0% vs 2.3%）
ePlus Inc.は米国発のコンサルティング型テクノロジーソリューションプロバイダーで、サイバーセキュリティ、クラウド、ネットワーク、コラボレーション、人工知能などの先進技術分野にわたり、5000社以上の顧客にソリューション、アドバイザリー、マネージドサービスを提供しています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
PLUS vs UTHR — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $614.8M | $790.2M |
| 純利益 | $35.1M | $364.3M |
| 粗利率 | 25.8% | 86.9% |
| 営業利益率 | 7.1% | 45.1% |
| 純利益率 | 5.7% | 46.1% |
| 売上前年比 | 20.3% | 7.4% |
| 純利益前年比 | 45.2% | 20.9% |
| EPS（希薄化後） | $1.33 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $614.8M | $790.2M | ||
| Q3 25 | $608.8M | $799.5M | ||
| Q2 25 | $637.3M | $798.6M | ||
| Q1 25 | — | $794.4M | ||
| Q4 24 | $493.2M | $735.9M | ||
| Q3 24 | $493.4M | $748.9M | ||
| Q2 24 | $535.7M | $714.9M | ||
| Q1 24 | — | $677.7M |
| Q4 25 | $35.1M | $364.3M | ||
| Q3 25 | $34.9M | $338.7M | ||
| Q2 25 | $37.7M | $309.5M | ||
| Q1 25 | — | $322.2M | ||
| Q4 24 | $24.1M | $301.3M | ||
| Q3 24 | $31.3M | $309.1M | ||
| Q2 24 | $27.3M | $278.1M | ||
| Q1 24 | — | $306.6M |
| Q4 25 | 25.8% | 86.9% | ||
| Q3 25 | 26.6% | 87.4% | ||
| Q2 25 | 23.3% | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | 25.4% | 89.7% | ||
| Q3 24 | 25.8% | 88.9% | ||
| Q2 24 | 23.7% | 89.1% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 7.1% | 45.1% | ||
| Q3 25 | 8.0% | 48.6% | ||
| Q2 25 | 5.7% | 45.6% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | 3.3% | 48.6% | ||
| Q3 24 | 5.5% | 45.8% | ||
| Q2 24 | 5.9% | 44.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | 5.7% | 46.1% | ||
| Q3 25 | 5.7% | 42.4% | ||
| Q2 25 | 5.9% | 38.8% | ||
| Q1 25 | — | 40.6% | ||
| Q4 24 | 4.9% | 40.9% | ||
| Q3 24 | 6.3% | 41.3% | ||
| Q2 24 | 5.1% | 38.9% | ||
| Q1 24 | — | 45.2% |
| Q4 25 | $1.33 | $7.66 | ||
| Q3 25 | $1.32 | $7.16 | ||
| Q2 25 | $1.43 | $6.41 | ||
| Q1 25 | — | $6.63 | ||
| Q4 24 | $0.91 | $6.23 | ||
| Q3 24 | $1.17 | $6.39 | ||
| Q2 24 | $1.02 | $5.85 | ||
| Q1 24 | — | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $326.3M | $2.9B |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $1.1B | $7.1B |
| 総資産 | $1.8B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $326.3M | $2.9B | ||
| Q3 25 | $402.2M | $2.8B | ||
| Q2 25 | $480.2M | $3.0B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | $253.1M | $3.3B | ||
| Q3 24 | $187.5M | $3.3B | ||
| Q2 24 | $349.9M | $3.0B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | $1.1B | $7.1B | ||
| Q3 25 | $1.0B | $6.6B | ||
| Q2 25 | $1.0B | $7.2B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | $962.3M | $6.4B | ||
| Q3 24 | $947.0M | $6.1B | ||
| Q2 24 | $921.9M | $5.7B | ||
| Q1 24 | — | $5.3B |
| Q4 25 | $1.8B | $7.9B | ||
| Q3 25 | $1.8B | $7.4B | ||
| Q2 25 | $1.8B | $7.9B | ||
| Q1 25 | — | $7.7B | ||
| Q4 24 | $1.8B | $7.4B | ||
| Q3 24 | $1.7B | $7.1B | ||
| Q2 24 | $1.7B | $6.7B | ||
| Q1 24 | — | $6.5B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $-87.4M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $173.3M |
| FCFマージンFCF / 売上 | — | 21.9% |
| 設備投資強度設備投資 / 売上 | — | 21.9% |
| キャッシュ転換率営業CF / 純利益 | -2.49× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | — | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $-87.4M | $346.2M | ||
| Q3 25 | $-34.8M | $562.1M | ||
| Q2 25 | $-99.0M | $191.7M | ||
| Q1 25 | — | $461.2M | ||
| Q4 24 | $65.7M | $341.2M | ||
| Q3 24 | $-21.6M | $377.2M | ||
| Q2 24 | $97.1M | $232.2M | ||
| Q1 24 | — | $376.5M |
| Q4 25 | — | $173.3M | ||
| Q3 25 | — | $351.6M | ||
| Q2 25 | — | $129.5M | ||
| Q1 25 | — | $386.3M | ||
| Q4 24 | — | $254.5M | ||
| Q3 24 | — | $300.7M | ||
| Q2 24 | — | $187.1M | ||
| Q1 24 | — | $338.3M |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | — | 16.2% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 40.2% | ||
| Q2 24 | — | 26.2% | ||
| Q1 24 | — | 49.9% |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 5.6% |
| Q4 25 | -2.49× | 0.95× | ||
| Q3 25 | -1.00× | 1.66× | ||
| Q2 25 | -2.63× | 0.62× | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 2.72× | 1.13× | ||
| Q3 24 | -0.69× | 1.22× | ||
| Q2 24 | 3.55× | 0.83× | ||
| Q1 24 | — | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PLUS
| All Others Customer End Market | $107.0M | 17% |
| Technology Customer End Market | $89.4M | 15% |
| Health Care Customer End Market | $81.5M | 13% |
| Financial Services Customer End Market | $66.1M | 11% |
| Professional Services Reporting Unit | $64.1M | 10% |
| Security | $61.1M | 10% |
| State And Local Government And Educational Institutions | $59.9M | 10% |
| Managed Services Reporting Unit | $48.8M | 8% |
| Other Product | $21.1M | 3% |
| Collaboration | $13.4M | 2% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
